会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • ANTIMYCOTIC PHARMACEUTICAL COMPOSITION
    • 抗生物药物组合物
    • US20120022120A1
    • 2012-01-26
    • US13258324
    • 2010-04-09
    • Hirokazu KobayashiEiko KosugiNobuo Kubota
    • Hirokazu KobayashiEiko KosugiNobuo Kubota
    • A61K31/427A61P31/10
    • A61K9/7015A61K9/0014A61K9/08A61K31/4178
    • In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25° C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5° C. for 2 weeks after manufacture.
    • 在含有诸如卢可康唑和/或其盐的化合物的外用药物组合物中,包括在1大气压和25℃下处于液体状态的高级醇和/或二元酸的二酯, 不包括碳酸二酯,聚氧乙烯烷基醚和/或聚氧乙烯烯基醚。 本发明提供使用克罗他米通以外的溶剂,碳酸亚丙酯和N-甲基-2-吡咯烷酮作为增溶和空间稳定化的溶剂的制剂,具有以下性质:1)当由通式(1)表示的化合物和 /或其盐具有立体异构体,在60℃的保存条件下生产的化合物和/或其盐的立体异构体的量为3周时相对于总质量为1质量% 化合物和/或其盐在保存开始时; 2)制备后立即在20°C的恒温下保存时,制剂处于透明液体状态; 和3)当制剂在制备后在5℃下保存2周后,不沉积晶体。
    • 8. 发明授权
    • Infected nail of animal infected with fungus
    • 感染真菌感染的指甲
    • US09491933B2
    • 2016-11-15
    • US12810202
    • 2008-12-25
    • Nobuo KubotaTsuyoshi ShimamuraSaori Nagasaka
    • Nobuo KubotaTsuyoshi ShimamuraSaori Nagasaka
    • A61K48/00A01K67/00C12Q1/02C12Q1/18
    • A01K67/00A01K2207/10A01K2227/107A01K2267/0337C12Q1/025C12Q1/18
    • The invention can produce an infected nail of an animal and an infected animal model in which the nail plate and nail bed of the nail are sufficiently infected with a superficial fungus which were difficult to be produced in the past, and provides an evaluation method useful for development of a therapeutic agent for intractable infectious diseases such as tinea unguium using the nail and the infected animal model. For producing the infected nail of an animal and the infected animal model infected with a superficial fungus, an immunosuppressive component is administered to an animal in advance to decrease immunocompetence, and then, a superficial fungus is inoculated into the animal, whereby the infected nail of an animal and the infected animal model reflecting clinical manifestation in which the nail plate and nail bed of the nail are sufficiently infected with the superficial fungus can be produced with good reproducibility in a short period of time.
    • 本发明可以产生感染的动物指甲和感染的动物模型,其中钉子的甲板和甲板被过去难以产生的浅表真菌充分感染,并且提供了用于 使用指甲和感染动物模型开发难治性感染性疾病如癣菌的治疗剂。 为了产生受感染的动物指甲和感染表皮真菌的受感染动物模型,预先向动物施用免疫抑制成分以降低免疫能力,然后将表面真菌接种到动物中,由此将受感染的指甲 可以在短时间内以良好的再现性产生反映临床表现的动物和感染的动物模型,其中甲板的指甲板和甲床被表面真菌充分感染。
    • 9. 发明授权
    • Antimycotic pharmaceutical composition
    • 抗真菌药物组合物
    • US09050271B2
    • 2015-06-09
    • US13258324
    • 2010-04-09
    • Hirokazu KobayashiEiko KosugiNobuo Kubota
    • Hirokazu KobayashiEiko KosugiNobuo Kubota
    • A61K31/4178A61K9/70A61K9/00A61K9/08
    • A61K9/7015A61K9/0014A61K9/08A61K31/4178
    • In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25° C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether. Provided is a preparation using a solvent other than crotamiton, propylene carbonate, and N-methyl-2-pyrroridone as a solvent for solubilization and steric stabilization and having the following properties: 1) when a compound represented by the general formula (1) and/or a salt thereof has a stereoisomer, the amount of the stereoisomer of the compound and/or a salt thereof produced under a preservation condition of 60 degrees C. for 3 weeks is 1% by mass or less with respect to the total mass of the compound and/or a salt thereof at the beginning of preservation; 2) the preparation is in a clear liquid state when preserved at a constant temperature of 20° C. immediately after manufacture; and 3) no crystal is deposited when the preparation is preserved at 5° C. for 2 weeks after manufacture.
    • 在含有诸如卢可康唑和/或其盐的化合物的外用药物组合物中,包括在1大气压和25℃下处于液体状态的高级醇和/或二元酸的二酯, 不包括碳酸二酯,聚氧乙烯烷基醚和/或聚氧乙烯烯基醚。 本发明提供使用克罗他米通以外的溶剂,碳酸亚丙酯和N-甲基-2-吡咯烷酮作为增溶和空间稳定化的溶剂的制剂,具有以下性质:1)当由通式(1)表示的化合物和 /或其盐具有立体异构体,在60℃的保存条件下生产的化合物和/或其盐的立体异构体的量为3周时相对于总质量为1质量% 化合物和/或其盐在保存开始时; 2)制备后立即在20°C的恒温下保存时,制剂处于透明液体状态; 和3)当制剂在制备后在5℃下保存2周后,不沉积晶体。